Coherus Will Launch US Lucentis Biosimilar By 2021
Deal With Bioeq Pulls Forward Ranibizumab Launch By Two Years
Executive Summary
Buoyed by the success of its Udenyca pegfilgrastim biosimilar, Coherus has struck a deal with Bioeq to acquire commercialization rights to its biosimilar version of Lucentis (ranibizumab) in the US, eyeing a launch date of 2021.